Appeals court upholds patent on Merck's Vytorin
WASHINGTON Feb 7 (Reuters) - A U.S. appeals court on Thursday ruled that the patent on Merck & Co's cholesterol fighter Zetia and a related drug, Vytorin, was valid.
The U.S. Court of Appeals for the Federal Circuit did not discuss the ruling at length and simply affirmed a decision by a lower court in New Jersey.
The U.S. District Court for the District of New Jersey had ruled in April that the patent on Merck's cholesterol fighter Zetia and on Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc until the patent expires.
- Sierra Leone declares emergency as Ebola death toll hits 729 |
- S&P500 index posts worst fall since April; indexes down for July
- U.S. man sues soccer star Cristiano Ronaldo over CR7 trademark
- Israel, Palestinian militant groups agree to three-day Gaza truce |
- Moscow fights back after sanctions; battle rages near Ukraine crash site |